SynthesisCirculation research2017
Protein-Truncating Variants at the Cholesteryl Ester Transfer Protein Gene and Risk for Coronary Heart Disease.
Synthesis in Circulation research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 86 citations in OpenAlex.
- Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease.European heart journal · 2022Trial
- Pharmacological Inhibition of CETP (Cholesteryl Ester Transfer Protein) Increases HDL (High-Density Lipoprotein) That Contains ApoC3 and Other HDL Subspecies Associated With Higher Risk of Coronary Heart Disease.Arteriosclerosis, thrombosis, and vascular biology · 2022Trial
- Protective lipid-lowering variants in healthy older individuals without coronary heart disease.Open heart · 2021Trial
- Association of genetically proxied cholesteryl ester transfer protein inhibition with risk of intracranial aneurysms: a Mendelian randomization study.Neurosurgical review · 2026Article
- Drug targets for lipid modification and risk of type 2 diabetes: a cis-Mendelian randomization study.Cardiovascular diabetology · 2026Article
- Cholesteryl Ester Transfer Protein Deficiency and Hyperalphalipoproteinemia.Journal of atherosclerosis and thrombosis · 2025Review
- Quo Vadis after AEGIS: New Opportunities for Therapies Targeted at Reverse Cholesterol Transport?Current atherosclerosis reports · 2025Review
- A Comprehensive Review of the Genetics of Dyslipidemias and Risk of Atherosclerotic Cardiovascular Disease.Nutrients · 2025Review
- A fascinating association between HDL as a multi-potent particle and hypertension.Hypertension research : official journal of the Japanese Society of Hypertension · 2024Article
- Rare and common coding variants in lipid metabolism-related genes and their association with coronary artery disease.BMC cardiovascular disorders · 2024Article
- Cholesteryl Ester Transfer Protein (CETP) Variations in Relation to Lipid Profiles and Cardiovascular Diseases: An Update.Current pharmaceutical design · 2024Review
- Genome-Wide Association Study of Cardiovascular Resilience Identifies Protective Variation in theJournal of the American Heart Association · 2023Observational
- Novel and future lipid-modulating therapies for the prevention of cardiovascular disease.Nature reviews. Cardiology · 2023Review
- The Impact of Acute Nutritional Interventions on the Plasma Proteome.The Journal of clinical endocrinology and metabolism · 2023Article
- High-density lipoprotein revisited: biological functions and clinical relevance.European heart journal · 2023Review
- Heart Disease and Stroke Statistics-2023 Update: A Report From the American Heart Association.Circulation · 2023Review
- Can PCSK7 be A New Pharmaceutical Target?Journal of atherosclerosis and thrombosis · 2022Article
- Cholesteryl Ester Transfer Protein Inhibition Reduces Major Adverse Cardiovascular Events by Lowering Apolipoprotein B Levels.International journal of molecular sciences · 2022Review
- Genomic Strategies Toward Identification of Novel Therapeutic Targets.Handbook of experimental pharmacology · 2022Article
- HDL and Cholesterol Ester Transfer Protein (CETP).Advances in experimental medicine and biology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
65 authors at 13 institutions in 8 countries.
Funding
Abstract
rationaleTherapies that inhibit CETP (cholesteryl ester transfer protein) have failed to demonstrate a reduction in risk for coronary heart disease (CHD). Human DNA sequence variants that truncate the
objectiveTo test whether protein-truncating variants (PTVs) at the METHODS AND
resultsWe sequenced the exons of the
conclusionsCompared with noncarriers, carriers of PTV at
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.